Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies targeting oncogenic mutations. These therapies aim to serve broad genetically defined patient populations, overcome resistance, reduce wild-type toxicities, and penetrate the brain for central nervous system (CNS) diseases. They are advancing two programs: BDTX-1535, an EGFR MasterKey inhibitor for EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a RAF MasterKey inhibitor for KRAS, NRAS, and BRAF alterations in solid tumors. They also have BDTX-4876, targeting FGFR2/3 mutations, and another candidate targeting an undisclosed oncogene. We show 24 historical shares outstanding datapoints in our BDTX shares outstanding history coverage, used to compute BDTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BDTX market cap history over the course of time is important for investors
interested in comparing BDTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BDTX versus a peer is one thing; comparing
BDTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BDTX can fluctuate over the course of history.
With this page we aim to empower investors researching BDTX by allowing them to research the BDTX market cap history. |
Free BDTX Email Alerts:
Video: The Importance of Market Cap
